Dec 25, 2011 | PR-inside.com
Now Available: Jiwa Bio-Pharm Holdings Limited (2327) - Financial and Strategic SWOT Analysis Review
The company develops drugs for the treatment of gastro-intestinal, infectious, musculo-skeletal, and cerebro-cardiovascular disorders.
Bisphosphonate Antiresorptive Agent, Ibandronate Sodium Hydrate...
December 14, 2011 - Taisho Pharmaceutical Co., Ltd. [Head Office: Toshima-ku, Tokyo; President: Akira Uehara ] and Chugai Pharmaceutical Co., Ltd.
"Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018" Published
The report identifies the key trends shaping and driving the global osteoporosis therapeutics market.
On Call: Fosamax, Boniva, Actonel: Should anyone take these osteoporosis drugs?
Half of all women and a quarter of all men will suffer fractures from weak bones as they age.
Also on Topix